Artificial pancreas: the bridge to a cure for type 1 diabetes

Authors

  • H Thabit
  • R Hovorka
  • M Evans

DOI:

https://doi.org/10.1002/edn.207

Keywords:

type 1 diabetes mellitus, artificial pancreas, closed-loop insulin delivery

Abstract

Abstract

Tight glycaemic control in type 1 diabetes mellitus has been shown to be important for the prevention of long-term microvascular complications. Consequently, intensive insulin treatment has been advocated in the attempt to achieve normal glycaemia. This has proven challenging mainly due to an increased risk of hypoglycaemia associated with the intensive insulin regimen. Closed-loop systems for glucose control, designed to mimic the endocrine action of the healthy pancreas without human intervention, may provide a solution.

The vital component of a closed-loop system, often referred to as an artificial pancreas, is a computer-based algorithm. Other components include a real-time continuous glucose monitor and an infusion pump to titrate and deliver insulin. The role of the control algorithm is to translate, in real-time, the information it receives from the glucose monitor and to compute the amount of insulin to be delivered by the pump.

This review article describes the individual components of the artificial pancreas, and aims to highlight existing clinical evidence from studies performed on available artificial pancreas prototypes. Current limitations and obstacles facing this technology are reviewed, together with its potential direction in the future. By achieving normal glycaemia and reducing the risk of hypoglycaemia, the artificial pancreas could potentially improve the lives of patients with type 1 diabetes and act as a ‘bridge’ until a cure for type 1 diabetes is found.

Downloads

Download data is not yet available.

References

Group DP. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23:857–66.

Bruno G, Novell G, Panero F, et al The incidence of type 1 diabetes is increasing in both children and young adults in Northern Italy: 1984-2004 temporal trends. Diabetologia 2009;52:2531–5.

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The DCCT Research Group. N Engl J Med 1993;329:977–86.

Unger J, Parkin C. Hypoglycemia in insulintreated diabetes: a case for increased vigilance. Postgrad Med 2011;123:81–91.

Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169–76.

Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011;7:385–95.

Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005;28:1231–9.

Lin EH, Katon W, Von Korff M, et al Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004;27:2154–60.

Feldman B, Brazg R, Schwartz S, et al A continuous glucose sensor based on wired enzyme technology - results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol They 2003;5:769–79.

Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ2011;343:d3805.

Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593–8.

Bergenstal RM, Tamborlane WV, Ahmann A, et al Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311–20.

Choudhary P, Shin J, Wang Y, et al Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reducdon in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011;34:2023–5.

Magni L, Raimondo DM, Bossi L, et al Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007;1: 804–12.

Hovorka R, Canonico V, Chassin Lj, et al Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004;25:905–20.

El-Khatib FH, Russell SJ, Nathan DM, et al A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27.

Hovorka R, Allen JM, Ellen D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375 (9716):743–51.

Marchetti G, Barolo M, Jovanovic L, et al An improved PID switching control strategy for type 1 diabetes. IEEE Trans Biomed Eng 2008; 55 (3):857–65.

Steil GM, Rebrin K, Darwin C, et al. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344–50.

Castle JR, Engle JM, El Youssef J, et al Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282–7.

Kovatchev BP, Breton M, Man CD, et al. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009;3:44–55.

Wilinska ME, Blaha J, Chassin L.I, et al Evaluating glycemic control algorithms by computer simulations. Diabetes Technol Ther 2011;13:713–22.

Klonoff DC, Cobelli C, Kovatchev B, et al Progress in development of an artificial pancreas. J Diabetes Sci Technol 2009;3:1002–4.

Dassau E, Zisser H, Palerm CC, et al. Modular artificial beta-cell system: a prototype for clinical research. JDiabetes Sci Technol 2008;2:863–72.

Steil GM, Palerm CC, Kurtz N, et al The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402–8.

Hovorka R, Kumareswaran K, Harris J, et al Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ2011;342:d1855.

Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther 2009;11 (Suppl 1):S113–9.

Danne T, Kordonouri O, Holder M, et al Prevention of hypoglycemia by using Low Glucose Suspend function in sensor-aug-mented pump therapy. Diabetes Technol Ther 2011;13:1129–34.

Buckingham B, Chase HP, Dassau E, et al Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Gam 2010;33:1013–7.

Elleni D, Allen JM, Nodale M, et al. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Diabet Med 2010;27:480–4.

Cengiz E, Swan KL, Tamborlane WV, et al Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol Ther 2009;11:207–10.

Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90:450–9.

Ellen D, Allen JM, Kumareswaran K, et al Day-and-night closed loop (CL) glucose control in adolescents with type 1 diabetes (T1D) . Diabetes 2011;60 (Suppl 1) :A41.

Weinzimer SA, Steil GM, Swan KL, et al Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934–9.

Steil GM, Rebrin K Closed-loop insulin delivery - what lies between where we are and where we are going? Expert Opin Drug Deliv 2005;2:353–62.

Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. Diabetes Re S Clin Pract 2010;87:348–53.

Weinstein RL, Schwartz SL, Brazg RL, et al Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 2007;30:1125–30.

McGarraugh G, Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. Diabetes Technol Ther 2009;11:145–50.

Ellingsen C, Dassau E, Zisser H, et al. Safety constraints in an artificial pancreatic beta cell: an implementation of model predictive control with insulin on board. J Diabetes Sci Technol 2009;3:536–44.

Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673–82.

Turner BC, Jenkins E, Kerr D, et al The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001;24:1888–93.

Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005;11:55–64.

Downloads

Published

2012-10-01

How to Cite

Thabit, H., Hovorka, R., & Evans, M. (2012). Artificial pancreas: the bridge to a cure for type 1 diabetes. International Diabetes Nursing, 9(2), 56–60. https://doi.org/10.1002/edn.207

Issue

Section

Review Article